Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes
M Packer, CS Wilcox, JM Testani - Circulation, 2023 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
and sodium in the early proximal renal tubule, but the magnitude and duration of any …
[HTML][HTML] SGLT2 inhibitors: the sweet success for kidneys
A Dharia, A Khan, VS Sridhar… - Annual Review of …, 2023 - annualreviews.org
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …
Serum uric acid and diabetes: from pathophysiology to cardiovascular disease
N Katsiki, GD Dimitriadis… - Current pharmaceutical …, 2021 - ingentaconnect.com
Hyperuricemia, has been traditionally related to nephrolithiasis and gout. However, it has
also been associated with the development of type 2 diabetes mellitus (T2DM) and …
also been associated with the development of type 2 diabetes mellitus (T2DM) and …
[HTML][HTML] Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical …
D Banerjee, P Winocour, TA Chowdhury, P De… - BMC nephrology, 2022 - Springer
People with type 1 and type 2 diabetes are at risk of developing progressive chronic kidney
disease (CKD) and end-stage kidney failure. Hypertension is a major, reversible risk factor …
disease (CKD) and end-stage kidney failure. Hypertension is a major, reversible risk factor …
[HTML][HTML] Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled …
JC Laursen, N Søndergaard-Heinrich… - …, 2021 - thelancet.com
Background Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression
of diabetic kidney disease, possibly by reducing the proximal tubule transport workload with …
of diabetic kidney disease, possibly by reducing the proximal tubule transport workload with …
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
M Packer - European Heart Journal, 2023 - academic.oup.com
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major heart
failure events, an action that is statistically linked to enhanced erythropoiesis, suggesting …
failure events, an action that is statistically linked to enhanced erythropoiesis, suggesting …
Optimization of albuminuria-lowering treatment in diabetes by crossover rotation to four different drug classes: a randomized crossover trial
VR Curovic, N Jongs, MYAM Kroonen, EH Zobel… - Diabetes …, 2023 - Am Diabetes Assoc
OBJECTIVE Renin–angiotensin system (RAS) inhibitors decrease the urinary albumin to
creatinine ratio (UACR) but are ineffective in up to 40% of patients. We hypothesized that …
creatinine ratio (UACR) but are ineffective in up to 40% of patients. We hypothesized that …
Short‐term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA‐REG OUTCOME trial
SW Waijer, D Xie, SE Inzucchi, B Zinman… - Journal of the …, 2020 - Am Heart Assoc
Background Early reduction in albuminuria with an SGLT2 (sodium‐glucose cotransporter 2)
inhibitor may be a positive indicator of long‐term cardiovascular and renal benefits. We …
inhibitor may be a positive indicator of long‐term cardiovascular and renal benefits. We …
[HTML][HTML] Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes
VS Sridhar, CP Limonte, PH Groop, HJL Heerspink… - Diabetologia, 2024 - Springer
Current management of chronic kidney disease (CKD) in type 1 diabetes centres on
glycaemic control, renin–angiotensin system inhibition and optimisation of risk factors …
glycaemic control, renin–angiotensin system inhibition and optimisation of risk factors …
Impacts of sodium/glucose Cotransporter‐2 inhibitors on circulating uric acid concentrations: a systematic review and meta‐analysis
Background. Several trials have assessed the antihyperglycemic effects of sodium/glucose
cotransporter‐2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM). We …
cotransporter‐2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM). We …